Abstract
A novel series of 2-piperidinyl quinoline chalcones/amines (3-21) as structural analogues of quipazine were designed in order to find a promising candidate having antidepressant potential. They were synthesized, characterized and screened in vivo for their antidepressant potential by two behavioural models viz. forced swim test (FST) and learned helplessness test (LST). FST showed that compound 5, 8 and 17 reduced significantly the duration of immobility at 20 mg/kg, when compared with the control (p<0.001), and demonstrated comparable activity to clomipramine (p<0.001). LST further supported the antidepressant potential of these compounds. Furthermore, in 5-HTP-induced head-twitch test and yohimbine-induced mortality test, most active compound 5 increased the rate of head-twitching and the prevalence of mortality. Thus, the mechanism of action of the antidepressant effects of compound 1-(2,4-Dichlorophenyl)-3-[2- (piperidin-1-yl) quinolin-3-yl] prop-2-en-1-one (5) may be attributed to increased 5HT and NE level in the synapse.
Keywords: Antidepressant behavioral test, Chalcone, 5-HTP induced mouse head-twitch test, Molinspiration, 2-Piperidinyl quinoline, Quipazine, Reductive amination, Schiff’s base, Yohimbine toxicity potentiation test, catecholamines
Letters in Drug Design & Discovery
Title:Design, Synthesis and Evaluation of Novel 2-piperidinyl Quinoline Chalcones/ Amines as Potential Antidepressant Agents
Volume: 10 Issue: 1
Author(s): Obaid Afzal, Sandhya Bawa, Suresh Kumar, Rajiv Kumar and Md Quamrul Hassan
Affiliation:
Keywords: Antidepressant behavioral test, Chalcone, 5-HTP induced mouse head-twitch test, Molinspiration, 2-Piperidinyl quinoline, Quipazine, Reductive amination, Schiff’s base, Yohimbine toxicity potentiation test, catecholamines
Abstract: A novel series of 2-piperidinyl quinoline chalcones/amines (3-21) as structural analogues of quipazine were designed in order to find a promising candidate having antidepressant potential. They were synthesized, characterized and screened in vivo for their antidepressant potential by two behavioural models viz. forced swim test (FST) and learned helplessness test (LST). FST showed that compound 5, 8 and 17 reduced significantly the duration of immobility at 20 mg/kg, when compared with the control (p<0.001), and demonstrated comparable activity to clomipramine (p<0.001). LST further supported the antidepressant potential of these compounds. Furthermore, in 5-HTP-induced head-twitch test and yohimbine-induced mortality test, most active compound 5 increased the rate of head-twitching and the prevalence of mortality. Thus, the mechanism of action of the antidepressant effects of compound 1-(2,4-Dichlorophenyl)-3-[2- (piperidin-1-yl) quinolin-3-yl] prop-2-en-1-one (5) may be attributed to increased 5HT and NE level in the synapse.
Export Options
About this article
Cite this article as:
Afzal Obaid, Bawa Sandhya, Kumar Suresh, Kumar Rajiv and Quamrul Hassan Md, Design, Synthesis and Evaluation of Novel 2-piperidinyl Quinoline Chalcones/ Amines as Potential Antidepressant Agents, Letters in Drug Design & Discovery 2013; 10 (1) . https://dx.doi.org/10.2174/1570180811309010075
DOI https://dx.doi.org/10.2174/1570180811309010075 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
Current Medicinal Chemistry New Preparative Approaches for Micro and Nano Drug Delivery Carriers
Current Drug Delivery Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Current Targets for Anticancer Drug Discovery
Current Drug Targets Procedure for Identification and Characterization of Drugs Efficient Against Mammalian Prion: From a Yeast-Based Antiprion Drug Screening Assay to In Vivo Mouse Models
Infectious Disorders - Drug Targets Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology Ceramide and Sphingosine-1-Phosphate in Cell Death Pathways : Relevance to the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets Effects of Transition Metals in the Conversion Mechanism of Prion Protein and in the Pathogenesis of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets HIV-1 gp120 and Drugs of Abuse: Interactions in the Central Nervous System
Current HIV Research Structure-Function of Prolyl Oligopeptidase and its Role in Neurological Disorders
Current Medicinal Chemistry - Central Nervous System Agents Regulation of Gait and Balance: The Underappreciated Role of Neuronal Nicotinic Receptor Agonists
Current Pharmaceutical Design Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Green Tea Extract-Patents and Diversity of Uses
Recent Patents on Food, Nutrition & Agriculture Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening Intracellular Accumulation of Toxic Turn Amyloid-β is Associated with Endoplasmic Reticulum Stress in Alzheimer’s Disease
Current Alzheimer Research Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones
Current Medicinal Chemistry The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) Getting Rid of Intracellular Aβ - Loss of Cellular Degradation Leads to Transfer Between Connected Neurons
Current Pharmaceutical Design